Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Patient Registry to Evaluate Disease Progression in Patients With ENPP1 Deficiency and Infantile-Onset ABCC6 Deficiency (GACI Type 2)

NCT06302439 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT06302439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06302439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Patient Registry to Evaluate Disease Progression in Patients With ENPP1 Deficiency and Infantile-Onset ABCC6 Deficiency (GACI Type 2)
Lead sponsor
Inozyme Pharma
Phase
Observational
Overall status
Terminated
Start date
July 25, 2024
Completion date
August 28, 2026
Enrollment
54 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

atp-binding cassette subfamily c member 6 deficiency, ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency